What is the clinical evidence from this study?

Study design: Cross-Sectional. Population: Established ASCVD, including CVA (n=105). Intervention: Inclisiran. Primary outcome: Patient satisfaction.

What question did this study set out to answer?

This research aims to assess patient experiences with Inclisiran for managing LDL-C in individuals with a history of cerebrovascular accidents.

May 8, 2026European Stroke JournalOpen Access

Abstract Number: Esoc2026a2064 Enhancing LDL-C Management - Patient-Reported Experience of Inclisiran for Secondary Prevention: Real-World Evidence From Rural Primary Care Patients in England

View Full Paper

Ask AI

Bookmark

Key result

Inclisiran achieves ~87% patient satisfaction in ASCVD, with most preferring twice-yearly dosing over daily pills.

n=105

Why the study?

Does inclisiran improve patient satisfaction and adherence in adults with established ASCVD?

Key Points

This research aims to assess patient experiences with Inclisiran for managing LDL-C in individuals with a history of cerebrovascular accidents.
An anonymised patient survey conducted among adults with established ASCVD who received Inclisiran.
The survey included a 16-item questionnaire addressing various aspects of treatment experience.
Quantitative data were analyzed descriptively, and thematic analysis was applied to free-text responses.
Inclisiran was reported as easy to receive by 86.0%, with an overall satisfaction rate of 86.9%.
79.8% of patients preferred twice-yearly injections over daily oral therapy, indicating a reduction in pill burden.
Self-reported adherence was 100%, while only 10.1% had a good understanding of Inclisiran's mechanism.

Study Design

Type

Cross-Sectional (n=105)

Structured PICO

Does inclisiran improve patient satisfaction and adherence in adults with established ASCVD?

Population

105 adults with established ASCVD (including prior CVA) who received inclisiran between 2022 and 2024 in rural primary care in England.

Exposure

Inclisiran (twice-yearly injection)

Outcome

Patient-reported experience, satisfaction, adherence, and perceived impact on medication burden assessed via a 16-item questionnairepatient reported

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Inclisiran is highly acceptable and well-tolerated for secondary prevention in real-world primary care, with high patient satisfaction driven by reduced pill burden.

Cite This Study

Deaney et al. (2026) conducted a cross-sectional in Established ASCVD, including CVA (n=105). Inclisiran was evaluated on Patient satisfaction. Inclisiran was highly acceptable among primary care patients with ASCVD, with 86.9% reporting satisfaction and 79.8% preferring its twice-yearly injection over daily oral lipid-lowering therapy.

synapsesocial.com/papers/69fd7f86bfa21ec5bbf07fa7 https://doi.org/10.1093/esj/aakag023.1717

View Full Paper

Ask AI

Bookmark

Implication

Inclisiran is highly acceptable and well-tolerated for secondary prevention in real-world primary care, with high patient satisfaction driven by reduced pill burden.

Abstract Number: Esoc2026a2064 Enhancing LDL-C Management - Patient-Reported Experience of Inclisiran for Secondary Prevention: Real-World Evidence From Rural Primary Care Patients in England

Key Points

Study Design

Structured PICO

Discussion

Implication

Cite This Study

Abstract Number: Esoc2026a2064 Enhancing LDL-C Management - Patient-Reported Experience of Inclisiran for Secondary Prevention: Real-World Evidence From Rural Primary Care Patients in England

Key Points

Study Design

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Also Consider